Water dissolvable macrocyclic lactone cyclodextrin complexes
US11077134B1 · kind B1 · utility
Assignee
Inventor
Key dates
| Filing date | Dec 23, 2020 |
| Grant date | Aug 3, 2021 |
| Priority date | — |
| Expiry date | Dec 23, 2040 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K47/40
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Injectable Ivermectin solution is safely administrable to humans and animals used the disclosed technology. A macrocyclic lactone cyclodextrin complex which is completely dissolvable or dissolved in water in a ratio of at least 50 micrograms to 500 milligrams of the macrocyclic lactone complex per 5 milliliters of water. The macrocyclic lactone cyclodextrin complex is non-toxic, without using organic solvents, and in embodiments, formed by adding a surfactant to the macrocyclic lactone complex to water. The macrocyclic lactone cyclodextrin complex is Ivermectin or an Ivermectin derivative in some embodiments. The cyclodextrin complex is 2-hydroxypropyl-beta-cyclodextrin in some embodiments of the disclosed technology. The surfactant can be polysorbate 80 and is in a ratio of 0.01% to 25%, by weight, to said water. The water soluble complexes can be added to the water. The water-soluble complexes can have at least one of an anti-parasitic, anti-viral and anti-cancer complex.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.